Arrowhead Pharmaceuticals Receives UK Marketing Authorisation for REDEMPLO

Arrowhead Pharmaceuticals said the UK MHRA granted marketing authorisation for REDEMPLO (plozasiran) to treat adults with familial chylomicronaemia syndrome who have not responded adequately to diet and conventional triglyceride-lowering therapies. The company also said the treatment is available on the NHS in England and Wales following positive guidance. REDEMPLO is an RNAi therapy designed to lower extremely high blood triglyceride levels by silencing genes involved in the condition; the approval expands Arrowhead’s commercial reach. The article did not report financial results or a stock-price reaction.